Novozymes A/S
CSE:NZYM B

Watchlist Manager
Novozymes A/S Logo
Novozymes A/S
CSE:NZYM B
Watchlist
Price: 403 DKK -3.93%
Market Cap: 165.6B DKK
Have any thoughts about
Novozymes A/S?
Write Note

Novozymes A/S
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novozymes A/S
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Novozymes A/S
CSE:NZYM B
Accrued Liabilities
kr820m
CAGR 3-Years
12%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Chr Hansen Holding A/S
CSE:CHR
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
Photocat A/S
STO:PCAT
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Novozymes A/S
Glance View

Market Cap
165.6B DKK
Industry
Chemicals

Novozymes A/S is a global leader in biotechnology, focusing on the production of enzymes and microorganisms that enhance industrial processes. Founded in 1925 and based in Denmark, the company has consistently leveraged its deep scientific expertise to innovate solutions across various sectors, including agriculture, bioenergy, and food & beverage. By developing sustainable alternatives to traditional chemical processes, Novozymes not only improves efficiency for its clients but also helps minimize environmental impact. As industries continue to shift towards greener practices, Novozymes stands at the forefront of this transition, positioning itself as a pivotal player committed to driving sustainable development. For investors, Novozymes represents a compelling opportunity in a growing market driven by increasing awareness of sustainability and resource efficiency. The company boasts a diverse portfolio of products and a strong track record of profitability, sustained by its continuous investment in research and development. With a robust customer base spanning across more than 30 industries, Novozymes is well-equipped to capitalize on the expanding demand for bio-based solutions. Investors can find confidence in Novozymes' strategic focus on innovation and its ability to adapt to the evolving landscape of global sustainability goals, making it a strong candidate for those looking to invest in a future-oriented enterprise.

NZYM B Intrinsic Value
124.68 DKK
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Novozymes A/S's Accrued Liabilities?
Accrued Liabilities
820m DKK

Based on the financial report for Dec 31, 2023, Novozymes A/S's Accrued Liabilities amounts to 820m DKK.

What is Novozymes A/S's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
3%

Over the last year, the Accrued Liabilities growth was 18%. The average annual Accrued Liabilities growth rates for Novozymes A/S have been 12% over the past three years , 3% over the past five years .

Back to Top